BioPharma Resources

Drug Trial Radar · NCT06559306

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-(Milligram) mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 752 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

752

Planned (sponsor's estimate)

Start

Jul 25, 2024

Primary completion

Dec 30, 2026

Study completion May 4, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Conditions

  • Depressive Disorder, Major

Interventions

  • SeltorexantDrug

    Seltorexant will be administered orally.

  • PlaceboDrug

    Matching Placebo tablets will be administered orally.

  • Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)Drug

    SSRI/SNRI will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Day 43Time frame: Baseline, Day 43
  2. Part 2: Time from Randomization to the First Relapse in Participants Who Achieve a Stable ResponseTime frame: Time from randomization to the first Relapse during the maintenance phase (up to 2 years and 10 months)

Locations

205 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Completed

  • Chandler Clinical Trials

    Chandler, Arizona · Completed

  • University of Arizona

    Tucson, Arizona · Recruiting

  • SanRo Clinical Research Group LLC WCG Clinical Network

    Bryant, Arkansas · Recruiting

  • Preferred Research Partners

    Little Rock, Arkansas · Completed

  • PAMOJA Clinical Institute LLC

    Anaheim, California · Recruiting

  • Axiom Research

    Colton, California · Recruiting

  • Elite Research Network 6

    Encino, California · Completed

  • Behavioral Research Specialists LLC

    Glendale, California · Recruiting

  • WR PRI Los Alamitos

    Los Alamitos, California · Completed

  • Excell Research Inc

    Oceanside, California · Recruiting

  • Prospective Research Innovations Inc

    Rancho Cucamonga, California · Completed

  • Anderson Clinical Research

    Redlands, California · Recruiting

  • Lumos Clinical Research Center LLC

    San Jose, California · Recruiting

  • Syrentis Clinical Research

    Santa Ana, California · Completed

  • California Neuroscience Research

    Sherman Oaks, California · Completed

  • Mountain View Clinical Research

    Denver, Colorado · Recruiting

  • UConn Health Center

    Farmington, Connecticut · Recruiting

  • Clinical Research of Brandon

    Brandon, Florida · Recruiting

  • AGA Clinical Trials

    Hialeah, Florida · Active not recruiting

  • Reliable Clinical Research

    Hialeah, Florida · Active not recruiting

  • Advanced Research Institute of Miami

    Homestead, Florida · Active not recruiting

  • Clinical NeuroScience Solutions Inc

    Jacksonville, Florida · Active not recruiting

  • Multi Specialty Research Associates Inc

    Lake City, Florida · Completed

  • Alcanza Clinical Research

    Largo, Florida · Completed

  • Pharmax Research Clinic Inc

    Miami, Florida · Active not recruiting

  • Miami Dade Medical Research Institute

    Miami, Florida · Active not recruiting

  • Nuovida Research Center

    Miami, Florida · Recruiting

  • Aqualane Clinical Research

    Naples, Florida · Completed

  • Bravo Health Care Center

    North Bay Village, Florida · Completed

  • Nova Psychiatry INC

    Orlando, Florida · Active not recruiting

  • Florida Center for TMS

    Saint Augustine, Florida · Completed

  • University of South Florida

    Tampa, Florida · Completed

  • Psych Me Medical Research Inc

    Tampa, Florida · Recruiting

  • Interventional Psychiatry of Tampa Bay

    Tampa, Florida · Recruiting

  • Health Synergy Clinical Research

    West Palm Beach, Florida · Recruiting

  • Conquest Research

    Winter Park, Florida · Completed

  • Advanced Discovery Research

    Atlanta, Georgia · Active not recruiting

  • Agile Clinical Research Trials, LLC

    Atlanta, Georgia · Recruiting

  • iResearch Atlanta LLC

    Decatur, Georgia · Active not recruiting

Showing 40 of 205 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.